

# Hirofumi Yoshino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5014986/publications.pdf>

Version: 2024-02-01

36  
papers

1,955  
citations

331670

21  
h-index

345221

36  
g-index

37  
all docs

37  
docs citations

37  
times ranked

3130  
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>miR-99a-5p</i> induces cellular senescence in gemcitabine-resistant bladder cancer by targeting <i>SMARCD1</i> . <i>Molecular Oncology</i> , 2022, 16, 1329-1346.	4.6	13
2	Targeting of the glutamine transporter SLC1A5 induces cellular senescence in clear cell renal cell carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2022, 611, 99-106.	2.1	4
3	Significance of preoperative screening of deep vein thrombosis and its indications for patients undergoing urological surgery. <i>Investigative and Clinical Urology</i> , 2021, 62, 166.	2.0	0
4	EHHADH contributes to cisplatin resistance through regulation by tumor-suppressive microRNAs in bladder cancer. <i>BMC Cancer</i> , 2021, 21, 48.	2.6	19
5	Oncological outcome of neoadjuvant low-dose estramustine plus LHRH agonist/antagonist followed by extended radical prostatectomy for Japanese patients with high-risk localized prostate cancer: a prospective single-arm study. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 66-72.	1.3	5
6	Targeting NPL4 via drug repositioning using disulfiram for the treatment of clear cell renal cell carcinoma. <i>PLoS ONE</i> , 2020, 15, e0236119.	2.5	20
7	Potential new therapy of Rapalink1, a new generation mammalian target of rapamycin inhibitor, against sunitinib-resistant renal cell carcinoma. <i>Cancer Science</i> , 2020, 111, 1607-1618.	3.9	38
8	Characterization of <i>PHGDH</i> expression in bladder cancer: potential targeting therapy with gemcitabine/cisplatin and the contribution of promoter DNA hypomethylation. <i>Molecular Oncology</i> , 2020, 14, 2190-2202.	4.6	17
9	Oncogenic effects of RAB27B through exosome independent function in renal cell carcinoma including sunitinib-resistant. <i>PLoS ONE</i> , 2020, 15, e0232545.	2.5	19
10	Tumor-suppressive microRNA-223 targets WDR62 directly in bladder cancer. <i>International Journal of Oncology</i> , 2019, 54, 2222-2236.	3.3	16
11	Anatomical Variations of the Left Renal Vein During Laparoscopic Donor Nephrectomy. <i>Transplantation Proceedings</i> , 2019, 51, 1311-1313.	0.6	6
12	Dynamic compartmentalization of purine nucleotide metabolic enzymes at leading edge in highly motile renal cell carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 2019, 516, 50-56.	2.1	17
13	Potential tumor-suppressive role of microRNA-99a-3p in sunitinib-resistant renal cell carcinoma cells through the regulation of RRM2. <i>International Journal of Oncology</i> , 2019, 54, 1759-1770.	3.3	24
14	HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer. <i>International Journal of Oncology</i> , 2018, 53, 725-736.	3.3	22
15	Oral Propranolol in a Child With Infantile Hemangioma of the Urethra. <i>Urology</i> , 2018, 122, 165-168.	1.0	3
16	Bromodomain protein BRD4 inhibitor JQ1 regulates potential prognostic molecules in advanced renal cell carcinoma. <i>Oncotarget</i> , 2018, 9, 23003-23017.	1.8	28
17	Is It Safe to Use the Same Scissors After Accidental Tumor Incision During Partial Nephrectomy? Results of <i>In Vitro</i> and <i>In Vivo</i> Experiments. <i>Journal of Endourology</i> , 2017, 31, 391-395.	2.1	4
18	Regulation of ITGA3 by the dual-stranded microRNA-199 family as a potential prognostic marker in bladder cancer. <i>British Journal of Cancer</i> , 2017, 116, 1077-1087.	6.4	48

#	ARTICLE	IF	CITATIONS
19	PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2 <sup>1±</sup> -Targeting Therapy for Renal Cell Carcinoma. <i>Cancer Research</i> , 2017, 77, 6321-6329.	0.9	60
20	Downregulation of microRNA-1274a induces cell apoptosis through regulation of BMPR1B in clear cell renal cell carcinoma. <i>Oncology Reports</i> , 2017, 39, 173-181.	2.6	18
21	microRNA-210-3p depletion by CRISPR/Cas9 promoted tumorigenesis through revival of TWIST1 in renal cell carcinoma. <i>Oncotarget</i> , 2017, 8, 20881-20894.	1.8	57
22	The microRNA signature of patients with sunitinib failure: regulation of <i>UHRF1</i> pathways by <i>microRNA-101</i> in renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 59070-59086.	1.8	66
23	Regulation of <i>UHRF1</i> by dual-strand tumor-suppressor <i>microRNA-145</i> ( <i>miR-145-5p</i> and <i>miR-145-3p</i> ): inhibition of bladder cancer cell aggressiveness. <i>Oncotarget</i> , 2016, 7, 28460-28487.	1.8	93
24	The role of microRNAs in bladder cancer. <i>Investigative and Clinical Urology</i> , 2016, 57, S60.	2.0	75
25	Dual tumor suppressors <i>miR-139-5p</i> and <i>miR-139-3p</i> targeting <i>matrix metalloproteinase 11</i> in bladder cancer. <i>Cancer Science</i> , 2016, 107, 1233-1242.	3.9	115
26	Expression of the Tumor SuppressivemiRNA-23b/27bCluster is a Good Prognostic Marker in Clear Cell Renal Cell Carcinoma. <i>Journal of Urology</i> , 2014, 192, 1822-1830.	0.4	52
27	The tumor-suppressive microRNA-143/145 cluster inhibits cell migration and invasion by targeting <i>GOLM1</i> in prostate cancer. <i>Journal of Human Genetics</i> , 2014, 59, 78-87.	2.3	112
28	Tumour-suppressivemicroRNA-24-1inhibits cancer cell proliferation through targetingFOXM1in bladder cancer. <i>FEBS Letters</i> , 2014, 588, 3170-3179.	2.8	52
29	The MicroRNA Expression Signature of Bladder Cancer by Deep Sequencing: The Functional Significance of the miR-195/497 Cluster. <i>PLoS ONE</i> , 2014, 9, e84311.	2.5	142
30	Tumor suppressive <i>microRNA-135a</i> inhibits cancer cell proliferation by targeting the <i>MYC</i> oncogene in renal cell carcinoma. <i>Cancer Science</i> , 2013, 104, 304-312.	3.9	87
31	Aberrant expression of microRNAs in bladder cancer. <i>Nature Reviews Urology</i> , 2013, 10, 396-404.	3.8	200
32	Epithelial-mesenchymal transition-related microRNA-200s regulate molecular targets and pathways in renal cell carcinoma. <i>Journal of Human Genetics</i> , 2013, 58, 508-516.	2.3	78
33	Tumor suppressive <i>microRNA-143/145</i> cluster targets hexokinase <sup>2</sup> in renal cell carcinoma. <i>Cancer Science</i> , 2013, 104, 1567-1574.	3.9	118
34	Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. <i>Biochemical and Biophysical Research Communications</i> , 2012, 417, 588-593.	2.1	77
35	Tumor suppressive microRNA-1285 regulates novel molecular targets: Aberrant expression and functional significance in renal cell carcinoma. <i>Oncotarget</i> , 2012, 3, 44-57.	1.8	173
36	miR-218 on the genomic loss region of chromosome 4p15.31 functions as a tumor suppressor in bladder cancer. <i>International Journal of Oncology</i> , 2011, 39, 13-21.	3.3	73